Indian psychological well being app Lissun takes on AI with $3M and extra briefs

Psychological well being app Lissun baggage $3M for AI integration 

Psychological well being platform Lissun in India has scored $2.5 million in a pre-Collection A funding spherical led by RPSG Capital Ventures.

With its recent funds, the startup plans to combine AI into its suite of digital psychological well being options which goal corporates, colleges, and households of youngsters with neurodevelopmental circumstances. The brand new funds may even go to increasing their companies and rising their group.

Proceeds from this new investing spherical deliver its complete funding to $5 million. Lissun final raised over $1 million in seed funding in September of the earlier 12 months. 

Asan Medical Middle first to prescribe locally-approved imaginative and prescient loss DTx 

Asan Medical Middle (AMC), certainly one of South Korea’s greatest hospitals, has began prescribing a Korean-made digital therapeutic for visible impairment attributable to stroke. 

The mobile-based utility Vivid Mind gives coaching via digital actuality to boost a person’s response to visible stimuli. 

AMC formally prescribed the answer in September, 5 months after it was cleared by the Korean authorities – the third for a neighborhood DTx.

AMC professor Kang Dong-hwa, who developed Vivid Mind with Nunaps (a neighborhood firm he based), now plans to broaden their DTx to hospitals domestically and overseas.

Neurophet’s newest collab to foretell Alzheimer’s danger

Korean medical imaging AI firm Neurophet has introduced a brand new partnership that can develop a brand new Alzheimer’s illness prognosis platform. 

In a press release, the corporate stated it would collaborate with native biotechnology agency Aribio, which develops remedy for neurodegenerative ailments. 

They intend to combine Neurophet’s MRI-based picture evaluation software program with Aribio’s blood-based Alzheimer’s diagnostic check to detect early individuals with Alzheimer’s-positive amyloid beta protein deposits of their brains. 

Their resolution, based on a press launch, seeks to make Alzheimer’s testing extra accessible, lowering repeat testing with the pricey amyloid-PET imaging.  

Neurophet and Aribio’s collaboration builds on their current work within the international scientific trial of Aribio’s oral Alzheimer’s remedy AR1001, part 3. 

In July, Neurophet unveiled the Neurophet AQUA AD, its newest Alzheimer’s remedy prescription and monitoring software program.